Several clinical trials are ongoing either in osteosarcoma regardless of tumor genetic TP53 alteration (e.g., NCT04833582) or molecularly driven in pediatric cancer with selected TP53 alterations (e.g., AcSé-ESMART Arm C, NCT02813135). This evidence concerns the gene TP53 and neoplasm.